Unproven Stem-Cell “Therapy” for Autism: Bar on Routine Clinical Use; Permissible Only in Approved, Regulated Clinical Trials

1. Introduction

In YASH CHARITABLE TRUST v. UNION OF INDIA (30-01-2026), the Supreme Court of India (J.B. Pardiwala & R. Mahadevan, JJ.) addressed a public interest writ petition concerning the rampant promotion, prescription and administration of stem cell “therapy” as a purported treatment/cure for Autism Spectrum Disorder (ASD) by multiple clinics in India.

The petitioners (a disability-focused trust, a developmental paediatrician, a medical ethics forum, and a parent) alleged that clinics were commercially offering an unproven intervention outside the legal and ethical safeguards applicable to clinical trials, thereby exposing vulnerable children and families to potential harm and financial exploitation. The respondents included the Union of India, the National Medical Commission (NMC), the Indian Council of Medical Research (ICMR), and private entities alleged to be involved in such practices.

The case raised two core questions: (i) whether stem cell “therapy” for ASD can be offered as a routine healthcare service; and (ii) whether existing law provides a regulatory pathway for stem-cell research/clinical trials in ASD.

2. Summary of the Judgment

• PIL maintainable: The Court held the petition bona fide and raising issues of public importance.
• No routine/paid “stem cell therapy” for ASD: Offering stem cell interventions for ASD as a clinical service outside an approved and monitored research/clinical trial setting fails the reasonable standard of care expected of medical professionals.
• Consent/autonomy cannot legalise an unproven intervention: Informed consent requires “adequate information”; where evidence is lacking, “adequate information” itself is absent. Patient autonomy does not confer a right to demand any treatment.
• Stem cells are “drugs” under the Drugs Act, 1940: Even autologous stem cells used in ASD fall within the broad definition of “drug” as “substances” intended for treatment.
• Regulatory route depends on manipulation:
  • Stem-cell derived products (substantially manipulated) are “new drugs” under the NDCT Rules, 2019 and require the NDCT clinical-trial pathway.
  • Minimally manipulated/autologous same-procedure cells may not be “new drugs”, but their use in ASD is still restricted to clinical trial/research via Chapter IV (Biomedical and Health Research) and binding ethical guidelines.
• Executive order cannot override statutory rules: The Court held Clause 2(vi) of the DHR Order dated 03.03.2024 (stating no regulatory role for DHR in stem cell research) non est because it conflicts with Rules 17–18 of the NDCT Rules, 2019.
• Consequences: Non-compliant practitioners face professional misconduct proceedings; errant clinical establishments may face action under the Clinical Establishments (Registration and Regulation) Act, 2010.
• Transitional direction: Since some patients were already receiving such interventions, the Court directed the Secretary, MoHFW (with AIIMS and NMC) to propose a “best possible solution” for continuity until re-routing to trial institutions; matter treated as part-heard for further directions.

3. Analysis

3.1 Precedents Cited (and How They Shaped the Outcome)

A. Medical negligence/standard of care framework

The Court’s central doctrinal move was to decide permissibility of “stem cell therapy” for ASD primarily through the standard of care owed by medical professionals, rather than only through drug-regulatory classifications.

• Indian Medical Association v. V.P. Shantha and others and Bolam v. Friern Hospital Management Committee: The Court used these to ground the “Bolam Test” in Indian jurisprudence—whether a doctor acted in accordance with a practice accepted as proper by a responsible body of medical opinion. This enabled the Court to treat authoritative professional guidance (NMC/ICMR) as a benchmark for what is “acceptable practice”.
• Laxman Balkrishna Joshi v. Trimbak Bapu Godbole: Cited for the triad of duties—care in undertaking the case, choosing treatment, and administering treatment—supporting the Court’s view that offering an unvalidated intervention as routine care is inconsistent with the physician’s duty.
• Jacob Mathew v. State of Punjab, Kusum Sharma v. Batra Hospital, and M.A. Biviji v. Sunita and Others: These cases reaffirmed that doctors are protected when following accepted practice “of that day”, judged with available knowledge. The Court drew a decisive corollary: if authoritative bodies state an intervention is unproven/not recommended, routine clinical offering falls below reasonable care. M.A. Biviji was used as a caution that treatment must not be “discarded or obsolete”; the Court effectively treated unproven stem-cell “therapy” for ASD (outside trials) as falling into the impermissible zone of speculative practice.

B. Consent and patient autonomy

• Samira Kohli v. Dr. Prabha Manchandra and Another: This provided the template for “real and valid” consent requiring “adequate information” (nature, benefits, alternatives, substantial risks, and consequences of refusal). The Court held that where robust evidence of efficacy and risk profile is lacking, the doctor cannot supply “adequate information” in the required sense, and consent cannot legitimise routine use.
• Common Cause (A Registered Society) v. Union of India and Another: Chandrachud J.’s observation was relied upon to limit autonomy: consent allows accepting/refusing offered treatment but does not create a right to demand a particular treatment. This neutralised the Parents’ Forum argument that Article 21 choice compels availability of stem cell “therapy”.

C. Statutory interpretation: “drug” and regulatory supremacy

• Chimanlal Jagjivan Das Sheth v. State Of Maharashtra . and Ishwar Singh Bindra and Others v. State of U.P.: These were used to interpret Section 3(b)(i) of the Drugs Act, 1940 broadly—“drug” includes “substances” used for treatment, not merely “medicines”. The Court applied this to stem cells as corporeal substances intended for treatment/mitigation.
• State of M.P. v. G.S. Dall and Flour Mills and Jaiveer Singh v. State of Uttarakhand: These established that executive instructions cannot override statutory rules. This directly supported the finding that Clause 2(vi) of the DHR Order (03.03.2024) could not cut down the DHR’s oversight role embedded in Rules 17–18 of NDCT Rules, 2019.

D. High Court orders referenced (contextual, not controlling)

• Abhishek Agarwal & Anr. v. Union of India & Anr., W.P.(C) 5147/2019: Cited by private respondents to suggest permissibility. The Supreme Court treated such orders as limited to interim/administrative understanding and did not allow them to displace the Court’s standard-of-care and statutory-ethical analysis.
• Dalip Kaur and Anr. v. Union of India and Anr., WP(C) No. 6850/2023: The Delhi High Court’s interim order emphasising autonomy and allowing continuation was noted, but the Supreme Court reframed the question: permissibility cannot rest on autonomy alone where “adequate information” is structurally missing and professional guidance disapproves routine use.

3.2 Legal Reasoning (How the Court Reached the Rule)

A. The Court’s controlling test: “standard of care” over “label wars” (therapy vs product)

Respondents attempted to avoid regulation by characterising autologous stem cell intervention as a procedure rather than a product, arguing the Drugs Act regulates products/drugs, not medical procedures. The Court rejected any “default legality” from that distinction, holding:

• The permissibility of offering an intervention as routine care depends primarily on whether it is a sound and relevant medical practice accepted by the profession, given current knowledge.
• If authoritative medical bodies state it is unproven/not recommended, offering it routinely fails the duty of reasonable care.

B. Authoritative scientific-ethical baseline: EMRB-NMC + ICMR/DHR documents

The Court treated the following as decisive indicators of professional acceptability:

• EMRB-NMC Recommendations dated 06.12.2022 (approved by NMC on 28.03.2024): Stem cell therapy is not recommended for ASD in clinical practice; use/promotion/advertisement constitutes professional misconduct; only research via well-designed RCTs is encouraged.
• National Guidelines for Stem Cell Research, 2017 and Evidence Based Status of Stem Cell Therapy for Human Diseases, 2021: These stressed insufficient evidence for ASD, warned against exploitation and “predatory marketing”, and stated any stem cell use (beyond limited exceptions like haematopoietic transplantation for approved indications) must be within approved and monitored clinical trials; use outside trials is unethical/malpractice.

The Court explicitly discounted contrary reliance on:

• DTAB’s 84th Meeting Recommendations dated 27.08.2019: They were not adopted into a binding government communication (beyond the definition clarification) and were internally inconsistent (commercialisation “outside” one’s clinic vs within it).
• A purported MoHFW “list” emailed on 19.01.2023: Its formal status, authorship, and adoption were not established; it could not override evidence-based guidance.

C. Consent and autonomy: why “willingness to take risk” was insufficient

The Court applied Samira Kohli v. Dr. Prabha Manchandra and Another to hold that “adequate information” is a precondition to valid consent. Because the evidence base for stem cell use in ASD was described as insufficient/inconclusive, the doctor cannot truthfully provide the kind of risk-benefit disclosure the law assumes for “informed consent.” The Court also invoked “therapeutic misconception” (from ethical guidelines) to explain the ethical danger in marketing experimental interventions as treatment.

Patient autonomy was further limited using Common Cause (A Registered Society) v. Union of India and Another: consent is the right to accept/refuse what is offered, not to compel what must not ethically be offered as routine care.

D. The “drug” finding: broad statutory inclusion, narrow “new drug” classification

• Under Section 3(b)(i) of the Drugs Act, 1940, stem cells are “substances” intended for treatment/mitigation and therefore fall within “drug”.
• Under NDCT Rules, 2019, only stem-cell derived products meeting the “substantial or more than minimal manipulation” threshold are always “new drugs” (Rule 2(1)(w)(v) with its Explanation).
• The Court relied on the MoHFW clarification dated 09.02.2021 (under Section 33P) to explain “minimal” vs “substantial” manipulation and noted that same-procedure autologous use typically does not become a “stem-cell derived product”.

Critically, the Court held that “not being a new drug” does not mean “free to sell as routine treatment”; the standard-of-care and ethical-research constraints still apply.

E. Regulatory pathway and the DHR oversight dispute

The Court mapped two pathways:

1. Stem-cell derived products (new drugs): Full NDCT Rules clinical trial regime applies (Ethics Committee registration/oversight, Central Licensing Authority permission, GCP compliance, and trial subject safeguards).
2. Other stem cell uses (not new drugs): Treated as “biomedical and health research” under Chapter IV of NDCT Rules, 2019, but made subject to binding ethical requirements (via Rules 15 and 16(4))—including that stem cell use (outside haematopoietic transplantation for specified disorders) must be conducted as clinical trials with appropriate approvals.

The dissolution of NAC-SCRT (Order dated 03.03.2024) created ambiguity. However, the Court resolved a key constitutional-administrative conflict: Clause 2(vi) of that order (“No regulatory role is anticipated to be carried out by DHR related to stem cell research”) could not override Rules 17–18 of NDCT Rules, 2019, which give DHR a supervisory role over Ethics Committees. Applying Jaiveer Singh v. State of Uttarakhand and State of M.P. v. G.S. Dall and Flour Mills, the Court held Clause 2(vi) non est.

3.3 Impact

A. On clinical practice (ASD and beyond)

• The judgment effectively establishes that clinics cannot offer stem cell interventions for ASD as a paid routine service, because doing so is inconsistent with the standard of care and constitutes unethical practice/professional misconduct when authoritative bodies disapprove.
• The Court’s reasoning is not ASD-specific in logic: whenever an intervention is unproven and disapproved by authoritative medical bodies, routine offering risks violating the standard of care. This approach may influence disputes concerning other experimental interventions marketed to vulnerable patients.

B. On professional discipline and enforcement architecture

• The Court strengthens the enforceability of ethical guidance by linking it to:
  • NMC/EMRB’s professional misconduct framework; and
  • IMC Regulations, 2002 continuing via Section 61(2) of the NMC Act, 2019 (especially Regulation 7.22 on research and ICMR guideline compliance).
• Clinical establishments face exposure under the Clinical Establishments (Registration and Regulation) Act, 2010 (Sections 32 and 40) for cancellation/penalty.

C. On regulation of stem cell research

• The judgment highlights a structural weakness: fragmented regulation and a vacuum created after dissolution of NAC-SCRT. The Court calls for MoHFW to clarify/regroup the oversight mechanism and suggests re-constituting NAC-SCRT and consolidating rules into dedicated legislation.
• The Court’s holding that Clause 2(vi) of the 03.03.2024 Order is non est protects the principle that executive restructuring cannot remove statutory oversight.

D. Transitional relief and practical governance

• By directing MoHFW (with AIIMS and NMC) to propose continuity solutions for existing patients, the Court balanced patient welfare concerns with the prohibition on continued commercialisation—signalling that compliance transitions must be managed, not abruptly imposed without pathways to lawful trial-based access.

4. Complex Concepts Simplified

• “Bolam Test”: A doctor is generally not negligent if their conduct aligns with a practice accepted as proper by a responsible body of medical professionals. Here, the Court treated ICMR/NMC positions as indicating what is (and is not) accepted practice.
• “Standard of care”: Not the “best possible” care, but what a reasonably competent doctor would do given present knowledge. Unproven interventions marketed as treatment fall outside that standard.
• “Drug” vs “new drug”: Many things can be “drugs” under the Drugs Act, 1940. Only certain categories (including substantially manipulated stem-cell derived products) are always “new drugs” under NDCT Rules, triggering stricter trial licensing.
• Minimal vs substantial manipulation (stem cells): Minimal handling like washing/centrifugation/freezing is treated differently from processes that change cell function or involve expansion/genetic modification. The latter are regulated as “stem-cell derived products/new drugs”.
• “Therapeutic misconception”: When patients/guardians wrongly believe participation in an experimental intervention is primarily intended to treat them like routine care, rather than to generate scientific knowledge. The Court saw commercial marketing of unproven stem-cell interventions as a prime setting for this misconception.
• Why “consent” was insufficient here: Consent in law presupposes the doctor can disclose adequate, evidence-based information. Where evidence is missing, the law’s model of informed consent breaks down.

5. Conclusion

YASH CHARITABLE TRUST v. UNION OF INDIA sets a clear rule: stem cell interventions for ASD cannot be offered as routine clinical services or commercial treatments because they are not recognised as sound and relevant medical practice on current evidence and are disapproved by authoritative bodies; they may be pursued only within approved and monitored clinical trial/research settings.

The Court’s doctrinal significance lies in its synthesis of (i) medical negligence “standard of care” jurisprudence, (ii) consent/autonomy limits, and (iii) drug-and-trial regulation—while also reinforcing that executive action cannot dilute statutory safeguards. The judgment thus functions both as a patient-protection precedent and as a regulatory governance correction in a rapidly evolving biomedical domain.